UCB

Oct 24, 2023

FDA Approves PENBRAYA for Most Common Serogroups Causing Meningococcal Disease; BIMZELX Approved Moderate to Severe Plaque Psoriasis; FDA Approves BioMarin’s VOXZOGO; FDA Fast Track Designation to ANPD001 for Parkinson’s Disease; UCB Announces FDA Approval of ZILBRYSQ; EMA Granted Orphan Drug Designation to Lisata’s LSTA1

Jan 03, 2023

Gilead Buys Out Rights to Cancer Therapy from Jounce; FDA Places Clinical Hold on Biogen’s Orelabrutinib; Pfizer Announces Phase 3 BENEGENE-2 Study Result; FDA Approves MediWound’s NexoBrid; UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab; FDA Approves TG Therapeutics’ Briumvi

Jul 30, 2020

Roche-UCB’s $120M collaboration; Omega snags $85M; ExeVir raises $27M; GSK culls pipeline meds after failures

Dec 06, 2018

Roche signs Icagen; UCB devote $255M; Siemens Healthineers celebrates

Newsletter/Whitepaper